Denmark’s Novo Nordisk saw its shares rise as much as 13% to 659.20 kroner this morning, after it announced top-line results ...

One of Novo Nordisk's next-generation obesity shots to follow up on the success of Wegovy helped patients lose 22% of their ...

Novo Nordisk today announced topline results from a phase 1b/2a clinical trial with amycretin, a unimolecular GLP-1 and ...

Danish businesses are concerned about a possible trade conflict with the United States over Greenland, a major lobby group ...

Amycretin could give Novo a buzzy product in a newly competitive obesity market. It works similarly to existing GLP-1 ...

"Trump might forget about Greenland. But also, he might not. Nobody knows. He operates on whims," @anneapplebaum writes.

TD Cowen analyst Michael Nedelcovych maintained a Buy rating on Novo Nordisk (NVO – Research Report) today. The company’s shares closed ...

Stock prices for Novo Nordisk fell by about 3% at market open after the Biden administration selected its revolutionary drugs ...

Denmark PM Frederiksen emphasised over the call that Greenland, which is an autonomous part of the kingdom of Denmark, was ...

Novo Nordisk's financial strength is evident through its 74% historical average ROIC and 85% gross margin. See why I rate NVO ...

One of Novo Nordisk's next-generation obesity shots to follow up on its success with Wegovy helped patients lose 22% of their ...

Novo Nordisk today announced topline results from a phase 1b/2a clinical trial with amycretin, a unimolecular GLP-1 and amylin receptor agonist intended for once weekly ...